Abstract
Purpose
To investigate the clinical characteristics and visual outcome of cytomegalovirus retinitis in Korean patients with acquired immunodeficiency syndrome (AIDS) in the highly active antiretroviral therapy (HAART) era.
Methods
The medical records of 252 patients from Seoul National University Hospital who were diagnosed with AIDS between 2003 and 2006 were reviewed retrospectively. In addition, 15 patients (19 eyes) Having cytomegalovirus (CMV) retinitis with a minimum follow-up period of more than a year were included. Visual acuity, immune status, involved retinal area, and bilaterality were analyzed.
Results
All patients were treated with the HAART regimen and an anticytomegaloviral agent with the exception of two patients. In all patients, immune recovery developed and retinitis was inactivated. Moderate (≤ 0.4) and severe (≤ 0.1) visual loss developed in 10 (52%) eyes and 9 (47%) eyes, respectively. Retinal detachment and involvement of posterior pole accounted for more than 80% (8 out of 10) of moderate, and 88% (8 out of 9) of severe visual loss. Patients with bilateral retinitis were more likely to develop retinal detachment and visual loss. Delayed immune recovery was associated with moderate visual loss.
References
1. Seo SY, Park SJ, Hwang JY. . The alteration of the positive rate of cytomegalovirus IgG antibody among preschool period children. Korean J Pediatr. 2006; 49:51–5.
2. Drew WL, Mintz L, Miner RC. . Prevalence of cytomegalovirus infection in homosexual men. J Infect Dis. 1981; 143:188–92.
3. Gallant JE, Moore RD, Richman DD. . Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine. The Zidovudine Epidemiology Study Group. J Infect Dis. 1992; 166:1223–7.
4. Pertel P, Hirschtick R, Phair J. . Risk of developing cytomegalovirus retinitis in persons infected with the human immunodeficiency virus. J Acquir Immune Defic Syndr. 1992; 5:1069–74.
5. Kempen JH, Jabs DA, Wilson LA. . Risk of vision loss in patients with cytomegalovirus retinitis and the acquired immunodeficiency syndrome. Arch Ophthalmol. 2003; 121:466–76.
6. Thorne JE, Jabs DA, Kempen JH. . Incidence of and risk factors for visual acuity loss among patients with AIDS and cytomegalovirus retinitis in the era of highly active antiretroviral therapy. Ophthalmology. 2006; 113:1432–40.
7. Macdonald JC, Karavellas MP, Torriani FJ. . Highly active antiretroviral therapy-related immune recovery in AIDS patients with cytomegalovirus retinitis. Ophthalmology. 2000; 107:877–81.
8. Wohl DA, Kendall MA, Owens S. . The safety of discontinuation of maintenance therapy for cytomegalovirus (CMV) retinitis and incidence of immune recovery uveitis following potent antiretroviral therapy. HIV Clin Trials. 2005; 6:136–46.
9. Thorne JE, Holbrook JT, Jabs DA. . Effect of cytomegalovirus retinitis on the risk of visual acuity loss among patients with AIDS. Ophthalmology. 2007; 114:591–8.
10. Choe KW. Epidemiology of HIV/AIDS: Current Status, Trend and Prospect. J Korean Med Assoc. 2007; 50:296–302.
11. Park YS, Kim YK, Cho JY. . Clinical Features and Treatment of Cytomegalovirus Retinitis in Korea. Infect Chemother. 2006; 38:116–22.
12. Lim EA, Lim YW, Chung YT. Cytomegalovirus Retinopathy in Acquired Immunodeficiency Syndrome. J Korean Ophthal-mol Soc. 1993; 34:1055–9.
13. SH Hwang BO. Therapecutic Effect of Ganciclovir on Cytomegalovirus Retinitis. J Korean Ophthalmol Soc. 1996; 37:103–8.
14. Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial 4. Visual outcomes. Studies of Ocular Complications of AIDS Research Group in collaboration with the AIDS Clinical Trials Group. Ophthalmology. 1994; 101:1250–61.
15. Nguyen QD, Kempen JH, Bolton SG. . Immune recovery uveitis in patients with AIDS and cytomegalovirus retinitis after highly active antiretroviral therapy. Am J Ophthalmol. 2000; 129:634–9.
16. Holtzer CD, Jacobson MA, Hadley WK. . Decline in the rate of specific opportunistic infections at San Francisco General Hospital, 1994-1997. AIDS. 1998; 12:1931–3.
17. Jacobson MA, Stanley H, Holtzer C. . Natural history and outcome of new AIDS-related cytomegalovirus retinitis diagnosed in the era of highly active antiretroviral therapy. Clin Infect Dis. 2000; 30:231–3.
18. Jabs DA, Van Natta ML, Kempen JH. . Characteristics of patients with cytomegalovirus retinitis in the era of highly active antiretroviral therapy. Am J Ophthalmol. 2002; 133:48–61.
19. Holbrook JT, Jabs DA, Weinberg DV. . Visual loss in patients with cytomegalovirus retinitis and acquired immunodeficiency syndrome before widespread availability of highly active antiretroviral therapy. Arch Ophthalmol. 2003; 121:99–107.
20. Kempen JH, Jabs DA, Dunn JP. . Retinal detachment risk in cytomegalovirus retinitis related to the acquired immuno-deficiency syndrome. Arch Ophthalmol. 2001; 119:33–40.
21. Whitcup SM, Fortin E, Lindblad AS. . Discontinuation of anticytomegalovirus therapy in patients with HIV infection and cytomegalovirus retinitis. JAMA. 1999; 282:1633–7.
22. Thorne JE, Jabs DA, Kempen JH. . Causes of visualacuity loss among patients with AIDS and cytomegalovirus retinitis in the era of highly active antiretroviral therapy. Ophthalmology. 2006; 113:1441–5.
23. Holland GN, Buhles WC Jr., Mastre B, Kaplan HJ. A controlled retrospective study of ganciclovir treatment for cytomegalovirus retinopathy. Use of a standardized system for the assessment of disease outcome. UCLA CMV Retinopathy. Study Group. Arch Ophthalmol. 1989; 107:1759–66.
Table 1.
Patient-specific characteristics | |
---|---|
Age at diagnosis of CMV retinitis | 37.3±6.8 (30-53) years |
Male:Female | 14:1 (22:2)∏ |
Bilaterality | 4/15 (26.6%) (4/22, 18.1%)∏ |
Follow-up period | 36.2±25.7 (12-87) months |
Duration from diagnosis of AIDS to diagnosis of CMV retinitis | 23.5±37.1 (0-119) months |
MSM‡ exposure | 6/12 (50%) |
Nadir CD4 T cell count§ | 22.9±23.2 /µl |
CD4 T cell count at CMV retinitis diagnosis | 59.0±54.6 (5-160) /µl |
<50 /µl | 9 (60%) |
50-99 /µl | 2 (13.3%) |
≥100 /µl | 4 (26.6%) |
HIV viral load | 277,000±294,000 (53-750,000) /ml |
Table 2.
Table 3.
No∗ | TM† | Sex | Age | CMV Tx∗∗ | Initial VA∏∏ | Final VA | Reason‡‡‡ | Zone (post) †††† | Zone (ant) | CD4 | Immune recovery time |
---|---|---|---|---|---|---|---|---|---|---|---|
1 | Bi‡ | M | 40 | N†† | 1.0 | 0.8 | 2 | 2 | 138 | 0 | |
2-1 | M | 36 | G IV/IV‡‡ | 0.15 | NLP††† | RD§§§ | 2 | 3 | 26 | 417 | |
2-2 | M | 36 | G IV/IV | 0.08 | 0.06 | Macula∏∏∏ | 1 | 2 | 26 | 417 | |
3 | He§ | M | 39 | G IV | 0.7 | 0.5 | 2 | 2 | 160 | 0 | |
4 | He | M | 51 | G IV | 0.1 | LP | Macula | 1 | 2 | 26 | 36 |
5 | Ho∏ | M | 30 | G IV/IV | 0.9 | 0.4 | ERM### | 1 | 1 | 11 | 173 |
6-1 | Ho | M | 32 | G IV/IV/F§§ | 0.4 | 0.08 | RD | 2 | 3 | 10 | 156 |
6-2 | Ho | M | 32 | G IV/IV/F | 0.6 | HM | Macula | 2 | 2 | 10 | 156 |
7-1 | He | M | 44 | G IV/IV | 0.9 | 0.6 | 2 | 2 | 40 | 161 | |
7-2 | He | M | 44 | G IV/IV | 0.9 | 0.6 | 3 | 3 | 40 | 161 | |
8 | He | M | 53 | G IV | 0.2 | 0.9 | 2 | 3 | 134 | 0 | |
9 | M | 31 | G IV/IV | LP## | NLP | Macula | 1 | 3 | 70 | 126 | |
10 | He | M | 33 | N | 0.2 | 0.04 | Cat‗‗‗‗ | 1 | 3 | 7 | 95 |
11 | Ho | M | 30 | G IV/O | 0.5 | 0.7 | 2 | 2 | 40 | 28 | |
12 | Ho | M | 33 | G IV/IV | HM‗‗‗ | NLP | RD | 1 | 3 | 5 | 145 |
13-1 | Ho | M | 39 | G IV/IV | 0.4 | 0.8 | 2 | 2 | 11 | 163 | |
13-2 | Ho | M | 39 | G IV/IV | 0.4 | LP | RD | 2 | 3 | 11 | 163 |
14 | M | 37 | G IV/IV | 0.9 | 1.2 | 1 | 2 | 110 | 0 | ||
15 | Tf# | F | 30 | G IV/IV | 0.7 | 1.0 | 2 | 2 | 98 | 92 |